Trading Idea OXGN >>
4 mensagens
|Página 1 de 1
Re: Trading Idea OXGN >>
Entrada longa ou curta?
Don't run a race that doesn't have a finish line.
Turney Duff
Turney Duff
-
- Mensagens: 666
- Registado: 20/8/2010 21:23
Re: Trading Idea OXGN >>
Luka! Escreveu:OXGN >> Grafico Actualizado (na Zona da MM200) que tem sido uma zona de entrada interessante nos ultimos tempos...
Boas Luka,
estarei a ver mal, ou MM200 está nos 3,38 ? e a cotação fechou hoje a 2,56 ?
o que me está a escapar ?
- Anexos
-
-
- Mensagens: 88
- Registado: 11/6/2012 0:00
Re: Trading Idea OXGN >>
OXGN >> Grafico Actualizado (na Zona da MM200) que tem sido uma zona de entrada interessante nos ultimos tempos...
- Anexos
-
- OXGN.png (28.48 KiB) Visualizado 760 vezes
... if you feel like doubling up a profitable position, slam your finger in a drawer until the feeling goes away !
-
- Mensagens: 3396
- Registado: 21/10/2003 21:48
Trading Idea OXGN >>
An Undervalued Opportunity In Biopharmaceuticals
•OXiGENE is an emerging small biopharmaceutical company listed on the Nasdaq.
•Its lead drug candidate could have a profound impact on the biopharmaceutical industry, but more importantly, ovarian cancer patients.
•We believe the company is significantly undervalued, and shares could trade higher soon.
A few months ago, we established a long position in an emerging micro-cap called OXiGENE Inc. (OXGN). This company operates in the biopharmaceutical industry, has a $55 million market cap and is listed on the NASDAQ. The chief reason that we initiated a long position is that we believe OXiGENE's ovarian cancer drug, ZYBRESTAT, has shown enough potential in clinical trials to warrant a partnership or buyout by a major pharmaceutical company in the coming months. We are also encouraged by the $30 million investment in the company by Symphony Capital LLC, which was unveiled today through a Life Sciences Report interview with the firm's co-founder, Mark Kessel. The company's three pipeline developments are:
1. ZYBRESTAT Combination therapies for the treatment of ovarian cancer and anaplastic thyroid cancer (ATC)
http://seekingalpha.com/article/2108163 ... aceuticals
•OXiGENE is an emerging small biopharmaceutical company listed on the Nasdaq.
•Its lead drug candidate could have a profound impact on the biopharmaceutical industry, but more importantly, ovarian cancer patients.
•We believe the company is significantly undervalued, and shares could trade higher soon.
A few months ago, we established a long position in an emerging micro-cap called OXiGENE Inc. (OXGN). This company operates in the biopharmaceutical industry, has a $55 million market cap and is listed on the NASDAQ. The chief reason that we initiated a long position is that we believe OXiGENE's ovarian cancer drug, ZYBRESTAT, has shown enough potential in clinical trials to warrant a partnership or buyout by a major pharmaceutical company in the coming months. We are also encouraged by the $30 million investment in the company by Symphony Capital LLC, which was unveiled today through a Life Sciences Report interview with the firm's co-founder, Mark Kessel. The company's three pipeline developments are:
1. ZYBRESTAT Combination therapies for the treatment of ovarian cancer and anaplastic thyroid cancer (ATC)
http://seekingalpha.com/article/2108163 ... aceuticals
- Anexos
-
- OXGN.png (20.7 KiB) Visualizado 814 vezes
... if you feel like doubling up a profitable position, slam your finger in a drawer until the feeling goes away !
-
- Mensagens: 3396
- Registado: 21/10/2003 21:48
4 mensagens
|Página 1 de 1
Quem está ligado:
Utilizadores a ver este Fórum: aaugustobb_69, Bing [Bot], CORTIÇA, danielme1962, Google [Bot], Jonas74, OCTAMA, PAULOJOAO e 246 visitantes